Navigation Links
Pacira Pharmaceuticals Names David M. Stack CEO and President

SAN DIEGO, Dec. 18 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., a leader in sustained release injectable technologies, today announced that David M. Stack has been selected as President, Chief Executive Office, and member of the Board of Directors.


Mr. Stack is currently the CEO and founding partner of Stack Pharmaceuticals, Inc., a commercialization, marketing and strategy firm serving emerging healthcare companies. He also is an Executive Partner at MPM Capital.

"David Stack is a proven, successful pharmaceutical executive with an exceptional blend of leadership and business skills," said Fred Middleton, Chairman of the Board. "We are confident that he is the ideal person to lead Pacira by enhancing the revenue opportunities of our existing commercial products, DepoDur and DepoCyt, optimizing the development and launch of our key asset, DepoBupivacaine, while further exploring the untapped promise of our proprietary drug delivery technologies."

Commenting on his appointment, Mr. Stack said, "I look forward to joining Pacira at this exciting time in its history. With strong financial backing by a pharmaceutical experienced syndicate, Pacira now has the opportunity to realize its potential by growing into a fully integrated, successful commercial company."

From September 2001 until August 2004, Mr. Stack was President, Chief Executive Officer and Director of The Medicines Company (Nasdaq: MDCO). Prior to The Medicines Company he was the CEO of Stack Pharmaceuticals, Inc. where MDCO was one of the primary customers.

From May 1995 to December 1999, Mr. Stack served as the President and General Manager of Innovex, Inc. and was responsible for the Americas. Innovex, Inc. is a commercial solutions company offering a full range of marketing, sales and clinical development capabilities to pharmaceutical and biotechnology customers.

Mr. Stack's prior experience also includes serving as the Vice President of Business Development and Marketing for Immunomedics, Inc. (Nasdaq: IMMU), as well as multiple senior business management positions at Roche Labs. Before he entered the commercial pharmaceutical sector, Mr. Stack was a retail and hospital pharmacist for three years after graduating from Albany College of Pharmacy. He also holds a BS in Biology from Siena College. Dave was recognized as the Ernst and Young Entrepreneur of the Year in 2003 (New Jersey Healthcare). He is a Director of Bio-Imaging Technologies, Inc. (Nasdaq: BITI), Medsite, Inc., PepTx, Inc. and QRxPharma Pty Ltd.

About Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals, Inc. is a wholly owned subsidiary of Pacira Inc., a Delaware corporation, which is controlled and funded by a group of financial investors including HBM BioVentures (Cayman) Ltd., MPM Capital, OrbiMed Advisors, and Sanderling Ventures. This business is based in San Diego, CA, and formulates, develops and manufactures controlled-release injectable products based on two proprietary drug delivery platforms: DepoFoam(R) and Biosphere(R). Revenues are generated from two marketed products: DepoCyt(R) for lymphomatous meningitis and DepoDur(R) for the treatment of post-surgical pain. For additional information about Pacira visit the Company's website at

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Flynn Pharma Acquires Rights From Pacira Pharmaceuticals to DepoDur(R), the Only Extended-Release Epidural Opioid for Post-Operative Pain, in Europe
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
(Date:11/27/2015)... ... ... ProSidebar: Fashion is a set of 30 kinetic edge graphics ... editors can easily add an informative sidebar to any FCPX production. Create lists, ... self-animating drop zones, lines, bars, and text with the ease of FCPX's drag and ...
(Date:11/27/2015)... ... 2015 , ... A simply groundbreaking television series, "Voices in America", which is ... an array of issues that are presently affecting Americans. Dedicated to providing the world ... is changing the subjects consumers focus on, one episode at a time. , ...
(Date:11/27/2015)... IL (PRWEB) , ... November 27, 2015 , ... ... of the largest, most successful and prominent nonprofit healthcare organizations in the country. ... governance involvement with various organizations, and helped advance the healthcare industry as a ...
(Date:11/26/2015)... ... 2015 , ... Patients at Serenity Point Recovery, a holistic ... Thanksgiving Day to share the things that they are most grateful for today. ... channel, patients displayed what they wrote on index cards, describing the things that ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... Netherlands , November 26, 2015 ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... Netherlands has found that immunotherapy can be ...
(Date:11/26/2015)... -- 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ... transplantation is expected to boost the market growth, as 3D ... --> 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ...
Breaking Medicine Technology: